Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

Litigation Details for CF Advance Corp. v. Thrasher (M.D. Fla. 2018)

Email this page to a colleague

« Back to Dashboard

CF Advance Corp. v. Thrasher (M.D. Fla. 2018)

Docket ⤷  Sign up for a Free Trial Date Filed 2018-10-19
Court District Court, M.D. Florida Date Terminated
Cause 28:1338 Patent Infringement Assigned To Carlos Eduardo Mendoza
Jury Demand None Referred To Daniel C. Irick
Patents 10,005,954; 7,462,758; 8,003,627; 8,034,755; 8,586,038; 8,754,011; 9,211,291; 9,757,471; 9,758,586
Attorneys Aaron T. Olejniczak; Andrew Scott Rapacke; Christopher R. Liro; Louis Raymond Gigliotti , Jr.; Mark Alexander Goldstein
Firms Andrus Intellectual Property Law LLP; Louis R. Gigliotti, Jr., PA; The Rapacke Law Group, P.A.
Link to Docket External link to docket
Small Molecule Drugs cited in CF Advance Corp. v. Thrasher
The small molecule drug covered by the patents cited in this case is ⤷  Sign up for a Free Trial .

Details for CF Advance Corp. v. Thrasher (M.D. Fla. 2018)

Date Filed Document No. Description Snippet Link To Document
2020-05-26 81 Amended Complaint Accordingly, claim 5 in the ’291 patent is the only original claim found patentable by the USPTO; original… 6 stand rejected as not patentable. 27. Claim 5 of the ’291 patent requires, among other limitations…substantial new question of patentability affecting claims 1-5 of United States Patent Number 9,744,627 is raised…014,212 rejecting the patentability of all original claims (1-5) in the ’627 patent. 32. On March… found patentable by the USPTO; original claims 1-5 all stand rejected as not patentable. 35 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.